- Home
- CUE vs BTAI Comparison
CUE vs BTAI Comparison
Compare CUE & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CUE | BTAI |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.1M | 35.6M |
| IPO Year | 2017 | 2018 |
Fundamental Metrics
Financial Performance| Metric | CUE | BTAI |
|---|---|---|
| Price | $0.31 | $1.56 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $3.00 | ★ $25.33 |
| AVG Volume (30 Days) | 343.6K | ★ 1.1M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 35.14 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $9,287,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $25.00 | $261.81 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 69.16 | N/A |
| 52 Week Low | $0.23 | $1.17 |
| 52 Week High | $1.12 | $8.08 |
Technical Indicators
Market Signals| Indicator | CUE | BTAI |
|---|---|---|
| Relative Strength Index (RSI) | 51.95 | 46.64 |
| Support Level | $0.26 | $1.50 |
| Resistance Level | $0.36 | $2.18 |
| Average True Range (ATR) | 0.02 | 0.14 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 65.48 | 31.58 |
Price Performance
Historical ComparisonAbout CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.